Kroin David's Form 4 filing
LB Pharmaceuticals Inc (LBRX) · filed Feb 10, 2026
- Accession no.
- 0001193125-26-044776
- Filed
- Feb 10, 2026, 4:30 PM ET
- Trade date
- Feb 6, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 0 non-derivative transactions and 2 derivative transactions. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kroin DavidCIK 0001397513 | 10% Owner |
| Deep Track Capital, LPCIK 0001856083 | 10% Owner |
| Deep Track Biotechnology Master Fund, Ltd.CIK 0002015536 | 10% Owner |
| Deep Track Special Opportunities Fund, LPCIK 0002077950 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | Common Stock | PPurchaseAcquired | +378,444 | $21.17 | +$8,011,621.64 | 378,444 | Direct | |
| Feb 6, 2026 | Common Stock | PPurchaseAcquired | +93,925 | $21.17 | +$1,988,382.86 | 93,925 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.